Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
Sponsor: Chong Kun Dang Pharmaceutical
Summary
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
Official title: A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-843 in Male Patients With Androgenetic Alopecia
Key Details
Gender
MALE
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
288
Start Date
2025-04-30
Completion Date
2027-09-17
Last Updated
2025-04-08
Healthy Volunteers
No
Conditions
Interventions
CKD-843 dose#1
IM injection every 3 months for 12 months
CKD-843 dose#2
IM injection every 3 months for 12 months
Placebo of CKD-843 dose
IM injection every 3 months for 12 months
Dutasteride Capsules
oral, once daily, 12 months
Placebo of Dutasteride Capsule
oral, once daily, 12 months
Locations (1)
Seoul National University Hospital
Seoul, South Korea